Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Revised postmenopausal treatments? A new polemic!].

J M Foidart1, J Desreux, A Pintiaux

  • 1Université de Liège, Département de Gynécologie-Obstétrique, Citadelle Liège.

Revue Medicale De Liege
|May 24, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Recent advances in thromboembolism and oral contraceptives.

Frontiers in endocrinology·2026
Same author

[Is there a place for stepped hormone assay in the development of hyperandrogenism?]

Revue medicale de Liege·2023
Same author

[Timing of gonadectomy in patients with complete androgen insensitivity syndrome].

Revue medicale de Liege·2022
Same author

[An update in intrauterine contraception].

Revue medicale de Liege·2022
Same author

[How to explore... hyperandrogenism associated with insulin resistance ? An example based on the HAIR-AN syndrome.]

Revue medicale de Liege·2021
Same author

[Breast cancer : individualized risk assessment for tailor-made screening].

Revue medicale de Liege·2021
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Estrogen-progestin therapy significantly increases breast cancer risk more than estrogen-only therapy. This analysis clarifies hormone replacement therapy risks for postmenopausal women.

Area of Science:

  • Endocrinology and Oncology
  • Epidemiology of Hormone Replacement Therapy

Context:

  • Hormone replacement therapy (HRT) is widely used by postmenopausal women.
  • Previous studies suggested HRT may increase breast cancer risk.
  • The specific risks associated with estrogen-only versus estrogen-progestin regimens require clarification.

Purpose:

  • To analyze the Schairer et al. study on breast cancer risk associated with HRT.
  • To clarify the actual figures of risk for estrogen and estrogen-progestin replacement therapy.
  • To provide guidance for physicians addressing patient concerns about HRT risks.

Summary:

  • A cohort study of 46,355 postmenopausal women (1980-1995) identified 2,082 breast cancer cases.
  • Estrogen-progestin use showed a higher increased relative risk (0.08/year) compared to estrogen-only (0.01/year) among recent users.

Related Experiment Videos

  • Increased risks were more pronounced in women with lower Body Mass Index.

    • Impact:

    • The estrogen-progestin regimen elevates breast cancer risk beyond estrogen-only therapy.
    • Clarifies media misinterpretations regarding relative risk versus attributable risk.
    • Offers evidence-based recommendations for clinicians managing HRT discussions.